# FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer

> **NCT01688336** · PHASE2 · TERMINATED · sponsor: **UNC Lineberger Comprehensive Cancer Center** · enrollment: 9 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** FOLFIRINOX

## Key facts

- **NCT ID:** NCT01688336
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-01
- **Primary completion:** 2016-08-22
- **Final completion:** 2016-11-22
- **Target enrollment:** 9 (ACTUAL)
- **Why stopped:** Results unlikely to impact treatment patterns. Time to complete not justified.
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01688336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01688336, "FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT01688336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*